These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 26823960)

  • 1. The PI3Kδ inhibitor idelalisib suppresses liver and lung cellular respiration.
    Hammadi SA; Almarzooqi S; Abdul-Kader HM; Saraswathiamma D; Souid AK
    Int J Physiol Pathophysiol Pharmacol; 2015; 7(3):115-25. PubMed ID: 26823960
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of molecularly targeted therapies on murine thymus: highly selective mTOR inhibitors induce reversible thymic involution.
    Al-Hammadi S; Almarzooqi S; Albawardi A; Souid AK
    Exp Hematol Oncol; 2015; 5():22. PubMed ID: 27478685
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Idelalisib induces apoptosis in the lymphoid tissues and impairs lung function in mice.
    George JA; Alshebli Z; Alneyadi A; Al Mukhaini N; Al-Salam S; Sudhadevi M; Souid AK; Alsuwaidi AR
    J Chemother; 2020 Apr; 32(2):88-97. PubMed ID: 31884896
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Idelalisib.
    Zirlik K; Veelken H
    Recent Results Cancer Res; 2018; 212():243-264. PubMed ID: 30069634
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Management of adverse events associated with idelalisib treatment: expert panel opinion.
    Coutré SE; Barrientos JC; Brown JR; de Vos S; Furman RR; Keating MJ; Li D; O'Brien SM; Pagel JM; Poleski MH; Sharman JP; Yao NS; Zelenetz AD
    Leuk Lymphoma; 2015; 56(10):2779-86. PubMed ID: 25726955
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro effects of platinum compounds on renal cellular respiration in mice.
    Almarzooqi SS; Alfazari AS; Abdul-Kader HM; Saraswathiamma D; Albawardi AS; Souid AK
    Int J Clin Exp Pathol; 2015; 8(1):81-95. PubMed ID: 25755695
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Idelalisib Impacts Cell Growth through Inhibiting Translation-Regulatory Mechanisms in Mantle Cell Lymphoma.
    Yang Q; Chen LS; Ha MJ; Do KA; Neelapu SS; Gandhi V
    Clin Cancer Res; 2017 Jan; 23(1):181-192. PubMed ID: 27342398
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Zoledronic acid and bone cellular respiration.
    Alsamri MT; Al-Hammadi S; Islam B; Souid AK
    J Bone Miner Metab; 2018 Jul; 36(4):392-398. PubMed ID: 28766136
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PI3Kδ inhibitor idelalisib in combination with BTK inhibitor ONO/GS-4059 in diffuse large B cell lymphoma with acquired resistance to PI3Kδ and BTK inhibitors.
    Yahiaoui A; Meadows SA; Sorensen RA; Cui ZH; Keegan KS; Brockett R; Chen G; Quéva C; Li L; Tannheimer SL
    PLoS One; 2017; 12(2):e0171221. PubMed ID: 28178345
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Idelalisib: A Novel PI3Kδ Inhibitor for Chronic Lymphocytic Leukemia.
    Shah A; Mangaonkar A
    Ann Pharmacother; 2015 Oct; 49(10):1162-70. PubMed ID: 26185276
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery of a Novel Inhaled PI3Kδ Inhibitor for the Treatment of Respiratory Diseases.
    Erra M; Taltavull J; Bernal FJ; Caturla JF; Carrascal M; Pagès L; Mir M; Espinosa S; Gràcia J; Domínguez M; Sabaté M; Paris S; Maldonado M; Hernández B; Bravo M; Calama E; Miralpeix M; Lehner MD; Calbet M
    J Med Chem; 2018 Nov; 61(21):9551-9567. PubMed ID: 30351000
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical use of PI3K inhibitors in B-cell lymphoid malignancies: today and tomorrow.
    Greenwell IB; Flowers CR; Blum KA; Cohen JB
    Expert Rev Anticancer Ther; 2017 Mar; 17(3):271-279. PubMed ID: 28112970
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Idelalisib: First-in-Class PI3K Delta Inhibitor for the Treatment of Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia, and Follicular Lymphoma.
    Yang Q; Modi P; Newcomb T; Quéva C; Gandhi V
    Clin Cancer Res; 2015 Apr; 21(7):1537-42. PubMed ID: 25670221
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PI3Kδ-selective and PI3Kα/δ-combinatorial inhibitors in clinical development for B-cell non-Hodgkin lymphoma.
    Lampson BL; Brown JR
    Expert Opin Investig Drugs; 2017 Nov; 26(11):1267-1279. PubMed ID: 28945111
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibitory Effect of Idelalisib, a Selective Phosphatidylinositol 3-Kinase δ Inhibitor, on Adipogenesis in an In Vitro Model of Graves' Orbitopathy.
    Ko J; Kim JY; Lee EJ; Yoon JS
    Invest Ophthalmol Vis Sci; 2018 Sep; 59(11):4477-4485. PubMed ID: 30193323
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The mTOR inhibitor sirolimus suppresses renal, hepatic, and cardiac tissue cellular respiration.
    Albawardi A; Almarzooqi S; Saraswathiamma D; Abdul-Kader HM; Souid AK; Alfazari AS
    Int J Physiol Pathophysiol Pharmacol; 2015; 7(1):54-60. PubMed ID: 26069529
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Idelalisib- a PI3Kδ targeting agent for B-cell malignancies.
    Hewett YG; Uprety D; Shah BK
    J Oncol Pharm Pract; 2016 Apr; 22(2):284-8. PubMed ID: 25712626
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synergistic Targeting of the Regulatory and Catalytic Subunits of PI3Kδ in Mature B-cell Malignancies.
    Cooney JD; Lin AP; Jiang D; Wang L; Suhasini AN; Myers J; Qiu Z; Wölfler A; Sill H; Aguiar RCT
    Clin Cancer Res; 2018 Mar; 24(5):1103-1113. PubMed ID: 29246942
    [No Abstract]   [Full Text] [Related]  

  • 19. The mTOR inhibitor sirolimus suppresses renal, hepatic, and cardiac tissue cellular respiration.
    Albawardi A; Almarzooqi S; Saraswathiamma D; Abdul-Kader HM; Souid AK; Alfazari AS
    Int J Clin Exp Pathol; 2015; 8(3):2955-62. PubMed ID: 26045804
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Management of Gastro-Intestinal Toxicity of the Pi3 Kinase Inhibitor: Optimizing Future Dosing Strategies.
    Breal C; Beuvon F; de Witasse-Thezy T; Dermine S; Franchi-Rezgui P; Deau-Fisher B; Willems L; Grignano E; Contejean A; Bouscary D; Faillie JL; Treluyer JM; Guerin C; Chouchana L; Vignon M
    Cancers (Basel); 2023 Apr; 15(8):. PubMed ID: 37190206
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.